Yi Huang

List of Publications by Year in Descending Order

31 papers	802 citations	15 h-index	28 g-index
35 ext. papers	1,170 ext. citations	7.3 avg, IF	4.46 L-index

#	Paper	IF	Citations
31	PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.. *Cancer Letters*, **2022**, 536, 215660	9.9	2
30	Immune-Related LncRNAs Affect the Prognosis of Osteosarcoma, Which Are Related to the Tumor Immune Microenvironment. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 731311	5.7	0
29	The role of tumor-associated macrophages in osteosarcoma progression - therapeutic implications. *Cellular Oncology (Dordrecht)*, **2021**, 44, 525-539	7.2	15
28	Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. *Cancer Letters*, **2021**, 500, 1-10	9.9	41
27	Macrophages-derived exosomal lncRNA LIFR-AS1 promotes osteosarcoma cell progression via miR-29a/NFIA axis. *Cancer Cell International*, **2021**, 21, 192	6.4	13
26	Chloroquine suppresses proliferation and invasion and induces apoptosis of osteosarcoma cells associated with inhibition of phosphorylation of STAT3. *Aging*, **2021**, 13, 17901-17913	5.6	2
25	Development of a Nomogram for Predicting the Efficacy of Preoperative Chemotherapy in Osteosarcoma. *International Journal of General Medicine*, **2021**, 14, 4819-4827	2.3	0
24	circUSP34 accelerates osteosarcoma malignant progression by sponging miR-16-5p. *Cancer Science*, **2021**, 113, 120	6.9	3
23	Quality of life and Q-TWiST were not adversely affected in Ewing sarcoma patients treated with combined anlotinib, irinotecan, and vincristine: (Peking University People's Hospital Ewing sarcoma trial-02, PKUPH-EWS-02).. *Medicine (United States)*, **2021**, 100, e28078	1.8	0
22	Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial **2020**, 8,		34
21	miR-100-5p Inhibits Malignant Behavior of Chordoma Cells by Targeting IGF1R. *Cancer Management and Research*, **2020**, 12, 4129-4137	3.6	6
20	Macrophages reduce the sensitivity of osteosarcoma to neoadjuvant chemotherapy drugs by secreting Interleukin-1 beta. *Cancer Letters*, **2020**, 480, 4-14	9.9	9
19	Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients. *Journal of Nanobiotechnology*, **2020**, 18, 151	9.4	19
18	Bone marrow mesenchymal stem cell-derived exosomal miR-206 inhibits osteosarcoma progression by targeting TRA2B. *Cancer Letters*, **2020**, 490, 54-65	9.9	41
17	LncRNA CASC15 is Upregulated in Osteosarcoma Plasma Exosomes and CASC15 Knockdown Inhibits Osteosarcoma Progression by Regulating miR-338-3p/RAB14 Axis. *OncoTargets and Therapy*, **2020**, 13, 12055-12066	4.4	13
16	Identification of Potential Therapeutic Targets and Immune Cell Infiltration Characteristics in Osteosarcoma Using Bioinformatics Strategy. *Frontiers in Oncology*, **2020**, 10, 1628	5.3	20
15	Development of a prognostic gene signature based on an immunogenomic infiltration analysis of osteosarcoma. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 11230-11242	5.6	12

List of Publications

14	Knockdown of HMGA2 regulates the level of autophagy via interactions between MSI2 and Beclin1 to inhibit NF1-associated malignant peripheral nerve sheath tumour growth. *Journal of Experimental and Clinical Cancer Research*, **2019**, 38, 185	12.8	14
13	Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways. *Cell Death and Disease*, **2019**, 10, 261	9.8	34
12	Apatinib plus camrelizumab (SHR-1210) for unresectable high-grade osteosarcoma (APFAO) progressing after chemotherapy: A prospective, open label, phase II trial.. *Journal of Clinical Oncology*, **2019**, 37, 11013-11013	2.2	2
11	Anlotinib, vincristine, and irinotecan for advanced Ewing sarcoma after failure of standard multimodal therapy: A multicenter, two-cohort, phase Ib/II trial (NCT03416517). **2019**, 5, 118-118		
10	Tumor-associated macrophages promote lung metastasis and induce epithelial-mesenchymal transition in osteosarcoma by activating the COX-2/STAT3 axis. *Cancer Letters*, **2019**, 440-441, 116-125	9.9	68
9	PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse. *Journal of Hematology and Oncology*, **2018**, 11, 16	22.4	68
8	miR-16-5p inhibits chordoma cell proliferation, invasion and metastasis by targeting Smad3. *Cell Death and Disease*, **2018**, 9, 680	9.8	55
7	Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3. *Biochemical and Biophysical Research Communications*, **2018**, 495, 1695-1701	3.4	54
6	Bortezomib induces apoptosis and suppresses cell growth and metastasis by inactivation of Stat3 signaling in chondrosarcoma. *International Journal of Oncology*, **2017**, 50, 477-486	4.4	16
5	Knockdown of long non-coding RNA HOTAIR increases miR-454-3p by targeting Stat3 and Atg12 to inhibit chondrosarcoma growth. *Cell Death and Disease*, **2017**, 8, e2605	9.8	76
4	BMPR2 promotes invasion and metastasis via the RhoA-ROCK-LIMK2 pathway in human osteosarcoma cells. *Oncotarget*, **2017**, 8, 58625-58641	3.3	20
3	Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signaling in osteosarcoma. *Cell Death and Disease*, **2017**, 8, e3015	9.8	131
2	BMPR2 and HIF1- overexpression in resected osteosarcoma correlates with distant metastasis and patient survival. *Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research*, **2017**, 29, 447-454	3.8	18
1	Induction of the mesenchymal to epithelial transition by demethylation-activated microRNA-125b is involved in the anti-migration/invasion effects of arsenic trioxide on human chondrosarcoma. *Journal of Experimental and Clinical Cancer Research*, **2016**, 35, 129	12.8	14